The rise of copyright’s drug initially ignited significant growth in the medicinal sector, creating a understanding of easy returns. However, placing capital in companies solely reliant on flagship drugs like Sildenafil presents considerable challenges. Exclusive rights end has resulted in generic challenge, decreasing sales portion and possibly

The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for game-changing treatments and impressive returns is certain, the linked risks are also considerable.